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The goal of this study was to elucidate the molecular mechanism
by which type I IFN inhibits assembly and release of HIV-1 virions.
Our study revealed that the IFN-induced ubiquitin-like protein
ISG15 mimics the IFN effect and inhibits release of HIV-1 virions
without having any effect on the synthesis of HIV-1 proteins in the
cells. ISG15 expression specifically inhibited ubiquitination of Gag
and Tsg101 and disrupted the interaction of the Gag L domain with
Tsg101, but conjugation of ISG15 to Gag or Tsg101 was not
detected. The inhibition of Gag-Tsg101 interaction was also de-
tected in HIV-1 infected, IFN-treated cells. Elimination of ISG15
expression by small interfering RNA reversed the IFN-mediated
inhibition of HIV-1 replication and release of virions. These results
indicated a critical role for ISG15 in the IFN-mediated inhibition of
late stages of HIV-1 assembly and release and pointed to a
mechanism by which the innate antiviral response targets the
cellular endosomal trafficking pathway used by HIV-1 to exit the
cell. Identification of ISG15 as the critical component in IFN-
mediated inhibition of HIV-1 release advances the understanding
of the IFN-mediated inhibition of HIV-1 replication and uncovers a
target for the anti HIV-1 therapy.
assembly  interferon inhibition  ubiquitination  ISG15
Type I IFN (IFN- and -) signaling is an essential componentof the innate antiviral response to infection. The biological
response to IFN is mediated by its binding to cell type specific
receptors, activation of the Jak–Stat signaling pathway and
stimulation of transcription of several hundreds of IFN-induced
genes (ISG) (1). Although some of the proteins encoded by these
genes have a direct antiviral activity (2), one group of IFN-
induced proteins are enzymes of the ubiquitin (Ub)-like pathway
and the Ub-like protein ISG15 (2, 3).
ISG15 was one of the first recognized ISGs (4). ISG15 is
covalently conjugated to targeted proteins through a series of
steps similar to ubiquitin conjugation. The ISG15 activating
enzyme is ubiquitin E1 like protein (UBE1L), and the major E2
enzyme for ubiquitin conjugation, UbcH8, also recognizes
ISG15 (5). An ISG15-specific ligase E3 has not yet been iden-
tified, but the IFN-induced Ub E3-like enzymes Rsp5 and
CEB1Hc5 may function in ISG15 conjugation (6, 7). Like Ub
(8), ISG15 is removed from conjugated proteins by an ISG15-
specific protease, UBP43 (9). Interestingly, type I IFN stimulates
expression not only of ISG15 but also UBEL1, UbcH8, and
UBP43 (3, 10) and markedly increases ISG15 conjugation.
ISG15 targets a large number of cellular proteins (7); however,
modification by ISG15 does not typically cause substrate deg-
radation (11).
Ub is a central cellular regulator (12), and Ub-mediated
proteolysis plays a regulatory role in the immune system (13). In
general, polyubiquitination targets proteins toward 26S pro-
tease-associated degradation, whereas monoubiquitination is a
signal for internalization and vesicle sorting. However, whereas
polyubiquitination on lysine 43 targets proteins for degradation,
lysine 63 polyubiquitination is a signal for kinase activation.
Many viruses modulate the Ub–proteasome pathway to alter
cellular signaling and the antiviral response (14, 15). HIV-1 uses
ubiquitination at two steps of its replication cycle. First, HIV-
1-encoded protein Vif targets cellular cytidine deaminase
APOBEC3G for Ub mediated degradation, thus preventing
APOBEC3G incorporation into viral particles and deamination
of the viral genome during reverse transcription (16–18). Vif
itself is monoubiquitinated and this may help its recruitment to
the site of viral assembly (19). Second, ubiquitination of Gag by
Ub ligase Nedd4.1 is critical for assembly and release of virions
from infected cells (20). HIV-1 assembly is driven by the Gag
poly protein (21), and deletion of the PTAP-L domain in p6 of
Gag, or inhibition of the Gag interaction with Tsg101, a protein
of the endosomal sorting complex (ESCRT-I) (22), results in
accumulation of HIV-1 virions at the plasma membranes.
An important role for type I IFN in the innate response to
HIV-1 infection is suggested by the observation that deletion of
high IFN producing dendritic pDC2 cells results in rapid pro-
gression of HIV-1 infection in vivo (23). In vitro, type I IFN
inhibits HIV-1 infection both at early steps of replication (24, 25)
and at the late steps of virus assembly and release (26–28).
HIV-1 virions assembled in IFN-treated T cells show a low
infectivity, accumulate at the plasma membrane, and have
altered morphogenesis (29–31). Similar defects were seen in
IFN-treated cells infected with murine leukemia virus (32). We
have shown that IFN-- and IFN--mediated inhibition corre-
lates with the induction of ISG15 (33).
The goal of this study was to further elucidate the role of
ISG15 in the IFN-mediated inhibition of HIV-1 replication and
to determine whether ISG15 interferes with the ubiquitination
steps critical for HIV-1 budding and release. We have found that
ectopic ISG15 mimics the IFN effect and inhibits release of
HIV-1 virions, but does not affect synthesis of HIV-1 proteins.
The elimination of ISG15 expression by small interfering RNA
(siRNA) rescues virus replication in IFN-treated cells. These
results implicate a critical role of ISG15 in the IFN-mediated
inhibition of HIV-1 budding and release.
Results
ISG15 Inhibits HIV-1 Replication. Type I IFN was shown to inhibit
HIV-1 replication at the late steps of virus assembly and release (25,
29, 34), and the IFN--mediated inhibition of HIV-1 replication
correlated with the induction of ISG15 (33, 35). Therefore, we have
examined whether overexpression of ISG15 can mimic the IFN
effect. Cells were transfected with HIV-1 provirus (NL43) alone or
in the presence of ISG15-expressing plasmid, and the levels of
released HIV-1 virions were analyzed by reverse transcriptase (RT)
assay. As shown in Fig. 1A, release of HIV-1 virions into the
medium was significantly inhibited in cells transfected with ISG15,
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and cotransfection of ISG15 with the ISG15-activating enzyme
UBE1L completely blocked HIV-1 replication. The expression of
the ISG15 deconjugating enzyme, UBP43, partially rescued HIV-1
released in ISG15-expressing cells (Fig. 1A). There was a direct
relation between the levels of ISG15 and inhibition of HIV-1
released to the medium evaluated both by the RT activity and the
levels of p24 in purified virions (Fig. 1B).
To determine whether ectopic ISG15 can also inhibit HIV-1
replication in HIV-1-infected cells, ISG15 was transduced by
lentivirus–vesicular stomatitis virus (VSV) pseudotype to U1.1
cells, which contain a single copy of latent HIV-1 provirus.
Because phorbol 12-tetradecanoate 13-acetate (TPA) treatment
induces HIV-1 replication in these cells; cells were treated with
TPA for 24 h before the ISG15 transduction. Levels of HIV-1
released into the medium were analyzed at different times after
TPA treatment and compared to the levels of virus released
from TPA-treated control cells (Fig. 1C). In TPA-treated U1.1
cells, HIV-1 virions were detected in the medium as soon as 36 h
after induction, with further increase at 48 and 96 h. Release of
HIV-1 virions from ISG15-transduced cells was inhibited over
this time period. The immune analysis of ISG15 expression in
transduced cell lysates showed the ectopic ISG15 expression at
24 h after transduction. Increased ISGylation of cellular proteins
was delayed and could be detected only at 36 h after transduc-
tion. Under the conditions when release of HIV-1 virions was
completely inhibited, the expression of the ectopic ISG15 did not
affect synthesis of HIV-1 proteins in the transduced cells (Fig.
1D), and the levels of Gag proteins were similar to those
expressed in TPA treated control U1.1 cells. These results
revealed that ectopic ISG15 expression inhibited released of
HIV-1 virions, but not the synthesis of viral protein in U1.1 cells.
ISG15 Inhibits Ubiquitination of Gag and Tsg101. The Gag polyprotein
and the PTAP motif of p6-Gag are necessary for the release of
HIV-1 particles from infected cells, and the link between the
ubiquitination of Gag and exocytosis of viral particles has been
established (36). Because ISG15, like Ub, is conjugated to cellular
proteins through lysine residues, and the ISG15 conjugation path-
way has been found to intersect the ubiquitination pathway, we
examined whether ectopic ISG15 modulates ubiquitination of Gag.
Cells were cotransfected with a Gag expression plasmid or its p6
deletion mutant and the Ub-expressing plasmid in the presence and
absence of ISG15 and UBE1L plasmids (Fig. 2A). Gag ubiquiti-
nation occurs in the absence of ectopic Ub by the endogenous Ub
pathway (Fig. 2B). Expression of Ub did not down-regulate Gag
levels, and even the p6 deletion mutant of Gag was ubiquitinated
at low levels. Previous observations suggested that ubiquitination
outside the p6 region may be functional, because the mutation of
the two ubiquitinated lysine residues in p6 region did not affect virus
release (37). However, in three independent experiments, the Gag
Fig. 1. ISG 15 inhibits HIV-1 replication. (A) HIV-1 (NL43) proviral DNA and plasmids expressing ISG15, UBE1L, or UBP43 (1 g) were cotransfected to 293T cells.
Supernatants were collected at indicated times after transfection, and the levels of released virus were analyzed by RT assay. (B) 293T cells were cotransfected
with plasmids expressing NL43 (2 g) and ISG15 (0 to 10 g), and 48 h after transfection; supernatants were collected for RT assay. The purified virions (Supporting
Text) were analyzed by immune blotting with p24 antibodies. The levels of transfected DNA were kept constant by the inclusion of plasmids DNA. (C) U1.1 cells
were first treated with TPA for 24 h and then infected with 301 ISG15 vector or 301 control vector that were VSV pseudotyped. At different times after TPA
treatment, supernatants were collected and the virus levels determined by the RT assay. (D) Cell lysates from TPA-treated U1.1 cells, infected with 301-ISG15 viral
vector (described in C) or the empty 301 vector, were analyzed at different times after TPA treatment by Western blot with HIV and ISG15 antibodies. The levels
of Gag proteins in TPA-treated U1.1 cells infected with an empty 301 vector at 48 and 72 h are shown.











ubiquitination was reduced in cells expressing ISG15 activating
enzyme UBEL1 (40%) and in cells that overexpressed both ISG15
and UBEL1 (55%). The differences between the levels of Gag
ubiquitination in the presence and absence of UBEL1 or ISG15 and
UBEL1 were found to be statistically significant (P  0.01).
Overexpression ISG15 alone without UBEL1 was not inhibitory
indicating that the cellular levels of UBEL1 and not ISG15 are
limiting. These data indicate that activation of the ISG15 conjuga-
tion results in the inhibition of Gag ubiquitination. Although the
ubiquitination of Gag was easily detected, we could not detect
conjugation of ISG15 to Gag polyprotein or the stabilized GFP–p6
fusion protein (38).
Tsg101 functions in sorting of vacuolar proteins (39). It contains,
in its N-terminal region, a domain related to ubiquitin-conjugating
enzyme E2, which is incapable of directly conjugating Ub but binds
to p6 of Gag polyprotein. Tsg101 also binds Ub (40) and is itself
ubiquitinated. Therefore, we examined whether ectopic ISG15
could also modulate ubiquitination of Tsg101 (Fig. 2C). Western
blot analysis of cellular lysates revealed a profound increase in the
ubiquitination of cellular proteins in Ub transfected cells. Expres-
sion of ectopic Ub resulted also in polyubiquitination of Tg101,
which was inhibited in cells expressing ectopic ISG15 and UBEL1,
but not ISG15 alone. Relative levels of Tsg101 were not significantly
altered in cells expressing either ectopic Ub or ISG15, and immu-
nodetection with ISG15 antibodies did not detect a presence of
ISGylated Tsg101 (data not shown).
ISG15 Inhibits Gag-Tsg101 Interaction. HIV-1 Gag polyprotein spe-
cifically interacts through p6 PTAP motif with Tsg101, and this
interaction is critical for HIV-1 budding (41). To understand the
mechanism by which ISG15 affects HIV-1 release, we have exam-
ined whether ISG15 modulates the association of Gag with Tsg101.
293T cells were cotransfected with both HIV-1 provirus (NL43)
and Tsg101-Flag or together with ISG15- and UBEL1-expressing
plasmids. The transfected cells were treated with the proteasome
inhibitor (MG132) to prevent possible degradation of Tsg101 and
to stabilize Gag-Tsg101 complex. Immunoprecipitation with
Tsg101 antibodies (Fig. 3A) and immunoblotting of the precipitates
with Gag antibodies detected Gag in immunoprecipitates of cell
lysates transfected with NL43 and Tsg101, but not in the cells that
were also expressing ISG15 or ISG15 and UBE1L. When UBP43
was expressed together with ISG15, low levels of the association
Fig. 2. ISG15 inhibits ubiquitination of Gag and Tsg101. (A) 293T cells were cotransfected with plasmids expressing optimized Gag or its p6 deletion mutant
Gag. When indicated, cells were also transfected with Ub-HA-, ISG15-, and UBE1L-expressing plasmids. Cell lysates were analyzed at 48 h after transfection by
Western blot with Gag polyclonal antibody (Upper), or immunoprecipitated with Gag and the precipitates analyzed by Western blot with anti-Ub monoclonal
antibody (Lower). The integrated density value of bands is based on the comparison with Gag-Ub (100%). (B) 293T cells were transfected with GFP-Gag and
GFP-Gag plasmids and the presence of Gag in lysates of transfected cells was determine by immunoblotting with Gag, GFP, or Ub antibodies. (C) Cells were
cotransfected with Tsg101, Ub-HA, and, when indicated, ISG15 and UBE1L expression plasmids. Cell lysates were analyzed 24 h after transfection by Western blot
with HA antibody (Top), or immunoprecipitated with Tsg101 antibody, and the precipitates were analyzed by immunoblotting with Tsg101 antibody (Middle)
or HA antibodies (Bottom). All of the analyses were done in two independent experiments.
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between Tsg101 and Gag could be detected. The association
between Tsg101 and Gag was confirmed by the reciprocal immu-
noprecipitation. Tsg101 could be detected in Gag precipitates of
NL43 and Tsg101-transfected cell lysates, but not in lysates of cells
that expressed ISG15 or ISG15 and UBP43. The levels of Gag were
comparable in all cells transfected with NL43 proviral DNA, and
ectopic Tsg101 was expressed at high levels in transfected cells.
These data indicate that ectopic ISG15 inhibits association of
Tsg101 with Gag and that this inhibition depends on ISG15
conjugation to the targeted proteins.
Inhibition of the Tg101-Gag association could be also seen in
IFN-treated cells that were cotransfected with NL43 proviral
DNA. Cells were transfected with NL43 DNA and, 24 h later,
treated with human IFN- for additional 48 h (when the
ISGylation to cellular proteins is substantially increased). Ly-
sates from IFN-treated and untreated cells were then immuno-
precipitated with Tsg101 antibody and the presence of Gag in the
precipitates was detected by immunoblotting with the Gag-
specific antibodies (Fig. 3B). Although the association of Tsg101
with Gag was detected in untreated cells, IFN treatment dis-
rupted this association. Expression of ectopic Tsg101 increased
the levels of Gag associated with Tsg101, but this association was
again disrupted in IFN-treated cells. These data show that the
levels of endogenous ISG15 induced by IFN are sufficient
enough to disrupt the Tsg101–Gag binding.
The ESCRT-I complex that interacts with ubiquinated Gag
protein comprises Tsg101, Vps28, and Vps 37 (22), where both
Vps37 and Vps28 bind to the C-terminal and central region of
Tsg101 (42). Ectopic ISG15 did not inhibit Tsg101–Vp28 inter-
action (Fig. 5, which is published as supporting information on
the PNAS web site).
ISG15 siRNA Reverses IFN-Mediated Inhibition. IFN induces a large
number of ISG proteins with antiviral functions that could also
contribute to the IFN-mediated inhibition of HIV-1 replication
(43–45). To determine the critical role of ISG15 in IFN-
mediated inhibition of HIV-1 assembly and release, we have
depleted the intracellular pool of ISG15 in IFN-treated, HIV-
1-infected cells. 293T cells were cotransfected with ISG15-
specific siRNA and HIV-1 provirus NL43 and, 48 h after
transfection, treated with IFN- for 24 h. As a control, cells were
also cotransfected with scrambled siRNA and HIV-1 provirus
NL43 (Fig. 4). The relative levels of ISG15 protein in the
IFN-treated cells transfected with ISG15-specific siRNA were
substantially lower in the presence of ISG15-specific siRNA than
Fig. 3. ISG15 inhibits Gag-Tsg101 interaction. (A) 293T cells were cotrans-
fected with NL43 proviral DNA and Tsg101 expressing plasmid and, when
indicated, also with ISG15 and UBE1L or UBP43 plasmids. Cell lysates (1 mg),
prepared 48 h after transfection, were immunoprecipitated with Tsg101 or
Gag antibody. The precipitates were analyzed by Western blot with Gag- or
Tsg101-specific antibodies. (B) 293T cells were cotransfected with NL43 pro-
viral DNA and, and when indicated, also with Tsg101-, UBE1L-, and UbcH8-
expressing plasmids. Twenty-four hours after transfection, cells were treated
with IFN- (500 unitsml) for 48 h and then cell lysates (1 mg) were immuno-
precipitated with Tsg101 antibody. The precipitates were analyzed by West-
ern blot with Gag antibody (Top) or Tsg101 antibody (Middle). Presence of
Gag in the cell lysates of transfected cells was determined by Western blot
(Bottom). All of the analysis was done in two independent experiments.
Fig. 4. Rescue of the IFN-mediated inhibition of HIV-1 release by ISG15
siRNA. 293T cells were cotransfected with NL43, ISG15 siRNA, or scrambled
siRNA, and 48 h after transfection, cells were treateduntreated with IFN-
(500 unitsml) for 24 h. HIV-1 virions in the supernatants were analyzed by the
RT assay. Cell lysates (20 g of proteins) were analyzed by Western blot with
ISG15 monoclonal antibody and the presence of Gag proteins was detected by
immunoblotting with human HIV-1 antiserum (Tulpin). As a control, cells were
transfected either with 10 nmol of siRNA or scrambled siRNA, and 48 h after
transfection, cell lysates were analyzed by Western blot with ISG15 monoclo-
nal antibodies.











in its absence or in cells that were transfected with the scrambled
siRNA. Transfection of IRF-5 siRNA or the scrambled siRNA
did not stimulate induction of ISG15. Neither IFN treatment nor
ISG15 or scrambled siRNA down-regulated the levels of Gag
proteins in the cells.
Although the release of HIV-1 virions was inhibited in
IFN-treated control cells, transfection of the ISG15 specific
siRNA reversed this inhibition. The IFN effect was not reversed
in cells transfected with the scrambled siRNA. These data
indicate that ISG15 is the key mediator of IFN-induced inhibi-
tion of HIV-1 release.
Discussion
We have shown in this study that the antiviral immune response
targets the ubiquitin-dependent pathway of HIV-1 budding and
release and that IFN-mediated inhibition is mediated by the
IFN-induced protein, ISG15. The data have also revealed that
expression of ectopic ISG15 and UBEL1 mimics the antiviral
effect of IFN and that the inhibition of ISG15 expression in IFN
treated cells by ISG15 specific siRNA, reverses IFN inhibition,
and rescues HIV-1 release.
Addressing the molecular mechanism of this inhibition, we have
shown that this inhibition occurs by altering protein interaction and
ubiquitination steps that are required for virus release. Ectopic
UBEL1 or UBEL1 and ISG15 inhibits the ubiquitination of HIV-
1-encoded Gag polypeptide and Tsg101 and the interaction of
Tsg101, a central component of ESCRT-1 with the p6 domain of
the Gag polyprotein. Tsg101 N-terminal UEV domain homologous
to E2 enzymes (46) binds to Ub, and this interaction is essential for
the targeting of Ub-conjugated proteins to multivesicular bodies
(47). However, Tsg101 UEV motif binds also to the P(TS)AP
motif in the L domain of HIV-1 Gag polypeptide, and the crystal
structure analysis revealed that the UEV domain can bind both Ub
and PTAP peptide simultaneously (48). The observation that
ISG15 interferes with ubiquitination of Gag and consequent release
of virus particles correlates with the previous observation, which
showed the inhibition of HIV-1 release in the presence of protea-
some inhibitors (49).
The precise mechanism by which ISG15 and UBEL1 interfere
with the HIV-1 Vps pathway is unclear. At this stage, we have
shown that expression of ectopic ISG15 and IFN-induced ISG15
prevents the Gag–Tsg101 interaction. Although we have not de-
tected ISGylation of Gag or Tsg101, ISG15 was shown to conjugate
to Ubc13 (7), Ub carrier protein E2. Ubc13 forms heterodimers
with Mms2, and these catalyze assembly of K63-linked polyubiq-
uitination (50). While this study was underway, it was shown that
ISGylation of Ubc13 suppresses its ability to form thioester inter-
mediates with Ub (51), which leads to inhibition of K63-linked
ubiquitination. Thus, the inhibition of Gag or Tsg101 ubiquitination
may be a consequence of ISGylation of Ubc13. The decrease in
ubiquitination of Gag and Tsg101 may then alter the binding
affinity of Tsg101 to Gag and destabilize the Tsg101–Gag complex.
In many retroviruses, there is a correlation between the L domain
and ubiquitination, where conjugated lysines are in a close prox-
imity to the L domain. Further investigations of the ISG15-
mediated effects are clearly warranted.
The functional consequences of ISG15 conjugation remain
unknown. ISG15 targets large numbers of cellular proteins, and
many of the ISGylated proteins are components of the antiviral
innate signaling pathway (7). Although it has been suggested that
ISGylation may increase the antiviral effect of IFN (52), mice
with homozygous deletion of ISG15 show neither defect in the
antiviral response against VSV and LCM nor enhanced STAT1
signaling (53). However, although a large number of cellular
proteins are ISGylated, the ISGylation of a virus-encoded
protein has not yet been demonstrated. Modification of Gag
protein by SUMO was described (54), but the conjugation of
ISG15 to Gag or GFP-p6 was not detected.
Several ISGs, such as PKR, ISG20, and 2-5AOS were implicated
in the inhibition of the early steps of HIV-1 replication (43–45).
Recently, expression of three cellular proteins, APOBEC3G
(A3G), APOBEC3F (A3F), and TRIM 5, was associated with
restriction of HIV-1 replication (55). TRIM 5 belongs to a family
of proteins with tripartite motif (56), some of which are stimulated
by IFN (57). TRIM blocks the early step of HIV-1 replication,
possibly by ubiquitination of the HIV-1 capsid protein (58). A3G
and A3F are APOBEC family proteins containing the cytidine
deaminase domain. A3G and A3F convert cytidine to uridine in the
single-stranded proviral DNA, which results in the hypermutation
of the HIV-1 genome (59). Although expression of A3G is not
stimulated by IFN in T cell line H9 (60), one of the ISGs, adenine
deaminase, catalyzes deamination of adenosine to inosine in viral
RNAs (61). Interestingly, the HIV-1-encoded Vif protein degrades
A3G by the Ub-mediated proteasome pathway by activated E3
ligase, Cullin 5 (17). Whether ISG15 affects also ubiquitination and
degradation of A3G is not known.
In conclusion, our data uncovered a mechanism in which the
innate antiviral response targets ubiquitination steps in HIV-1
replication cycle and identified an IFN-induced cellular protein,
ISG15, as the inhibitor of HIV-1 assembly pathway. The effect
of ISG15 may be at least partially related to the inhibition of Gag
and Tsg101 ubiquitination and to disruption of the interaction of
Gag L domain with Tsg101, although additional mechanisms
cannot be excluded. Number of retroviruses and negative strand
enveloped RNA viruses contain the L domains that have a
similar role in the endosomal trafficking pathway (62). Thus,
ISG15 may affect replication not only of HIV-1, but also of a
broad group of RNA viruses. Inhibition of murine leukemia
virus assembly in IFN treated cells has been demonstrated (63).
These results advance the understanding of previous findings
and uncover a target for anti-HIV-1 intervention. Possible
implications of these findings are the development of more
effective clinical therapies that will not have the side effects
associated with IFN treatment.
Materials and Methods
Cell Culture, Plasmids, and Virus. 293T cells were cultured in DMEM
with 10% FBS. PM-1, U937, and U1.1 cells were cultured in RPMI
medium 1640 with 10% FBS. The histidine-tagged Vps 28 (His-
Vps28) plasmid was generated by insertion of Vps28 cDNA into the
HindII and XhoI restriction sites of pcDNA 3.1 vector (Invitrogen).
The hemagglutinin (HA)-tagged Ub (Ub-HA) plasmid was ob-
tained from Heinrich Gottlinger (Harvard Medical School, Bos-
ton), and pISG15, UBE1L and the histidine-tagged ISG15 (ISG15-
His) have been described (64). The Flag-tagged Tsg101 plasmid
(Tsg101 Flag) was from Seth Welles (Harvard University, Boston),
the optimized GFP-Gag plasmid was from George Pavlakis (Na-
tional Cancer Institute, Frederick, MD), and the GFP–p6 fusion
plasmid was from Jeremy Luban (Columbia University, New York).
The lentiviral vector expression cassette 301 was obtained from
Y. N. Chang (Lentigen, Catonsville, MD). The HIV-1 provirus
NL43 and the macrophage-tropic HIV-1 AD8 were obtained from
Malcolm Martin (National Institutes of Health, Bethesda). Infec-
tious virus was produced and purified as described in Supporting
Text, which is published as supporting information on the PNAS
web site. HIV-1-NL43 provirus was derived from two North
American strains of HIV-1; its sequence and characterization are
described in ref. 65.
Lentivirus Vector Containing ISG15cDNA. The ISG15 cDNA was
cloned to NotI and BstEII restriction sites of lentiviral vector
301, containing a CMV-driven enhanced GFP (EGFP). Vector
301-ISG15 was cotransfected to 293T cells with the helper
plasmids pCMVR8.2 carrying Gag, pol, tat, and rev, the accessory
genes vif, vpr, vpu, and nef, and the pMDG plasmid encoding
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VSV-G protein. Preparation of virus stock was done according
to Davis et al. (66) and is described in Supporting Text.
Antibodies, Immunoprecipitation, Western Blot, and Statistical Anal-
ysis. The Tsg101, and ubiquitin antibodies were purchased from
Santa Cruz Biotechnology, HA antibodies were purchased from
Roche, Flag antibodies were purchased from Sigma, and the
Gag-specific antibodies were purchased from Advanced Bio-
technologies (Columbia, MD). ISG15 monoclonal antibody was
kindly provided by E. Borden (Cleveland Clinic, Cleveland).
Human serum, Tulpin, which detects HIV-1 proteins, was
generous gift from Malcolm Martin. The Western blot analysis
of cell lysates and immunoprecipitations (67) are described in
Supporting Text. Statistical analysis by t test and Student’s t test
were performed in EXCEL (Microsoft).
RT Assay. Supernatants collected from HIV-1 infected cells or
from cells transfected with HIV-1 proviral DNA at times
indicated were clarified by low-speed centrifugation and passed
through 0.45-m-pore-size filters. Virus was concentrated by
centrifugation on 20% sucrose cushions at 25,000 rpm for 1 h at
4°C. Pelleted virus was analyzed by RT assay as described (68).
ISG15 siRNA. ISG15-synthetic siRNA (G1P2) was purchased from
Ambion (Austin, TX) as annealed oligonucleotide and was resus-
pended in RNase-free H2O. 293T cells were cotransfected with
ISG15 siRNA (10 nmol), scramble siRNA (5 or 10 nmol as
indicated, purchased from Dharmacon RNA Technologies), and
NL43 by using Lipofectamine 2000 (Invitrogen). Forty-eight hours
after transfection, cells were treated with IFN- for 24 h. The levels
of ISG15 in cell lysates were determined by Western blot analyses.
We thank Dr. E. Borden for the generous gift of ISG15 antibodies and
Drs. Y.-N. Chang, H. Gottlinger, J. Luban, M. Martin, G. Pavlakis, and
S. Welles for the respective plasmids. These studies were supported by
National Institute of Allergy and Infectious Diseases Grants AI054537
and AI054276 (to P.M.P.).
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